Is BCDAW or MO a better dividend investment in 2026?

BCDAW currently yields 32786.89% with a 5% 5-year dividend growth rate. MO yields 6.27% with 4.3% growth. The better choice depends on your goal: BCDAW offers higher current income.

What is the dividend yield difference between BCDAW and MO?

BCDAW has a forward dividend yield of 32786.89% ($2.00/share annually). MO yields 6.27% ($4.20/share annually). The yield gap is 32780.62 percentage points.

Home › Compare › BCDAW vs MO

BCDAW vs MO: Dividend Comparison 2026

BCDAW yields 32786.89% · MO yields 6.27%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 BCDAW wins by $7.149378406802545e+21M in total portfolio value

INVESTMENT

TIME HORIZON10 years

BCDAW

● Live price

32786.89%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$7.149378406802545e+21M

Annual income

$7,106,739,309,572,423,000,000,000,000.00

Full BCDAW calculator →

Altria Group Inc.

● Live price

6.27%

Share price

$67.02

Annual div

$4.20

5Y div CAGR

22.6%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$77.7K

Annual income

$28,968.54

Full MO calculator →

Portfolio growth — BCDAW vs MO

📍 BCDAW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	BCDAW	MO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, BCDAW + MO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

BCDAW pays

MO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BCDAW

Annual income on $10K today (after 15% tax)

$2,786,885.25/yr

After 10yr DRIP, annual income (after tax)

$6,040,728,413,136,559,000,000,000,000.00/yr

Annual income on $10K today (after 15% tax)

$532.68/yr

After 10yr DRIP, annual income (after tax)

$24,623.26/yr

At 15% tax rate, BCDAW beats the other by $6,040,728,413,136,559,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BCDAW + MO for your $10,000?

BCDAW: 50%MO: 50%

100% MO50/50100% BCDAW

Portfolio after 10yr

$3.5746892034012726e+21M

Annual income

$3,553,369,654,786,211,600,000,000,000.00/yr

Blended yield

99.40%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

BCDAW

No analyst data

Altman Z

-75.0

Piotroski

2/9

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$61.25

-8.6% upside vs current

Range: $47.00 — $68.00

Altman Z

3.2

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BCDAW buys

MO buys

Politician	Chamber	Ticker	Type	Amount	Date
Ro Khanna	🏢 House	$MO	▲ Buy	$1,000 - $15,000	2025-08-04
Sheri Biggs	🏢 House	$MO	▼ Sell	$1,001 - $15,000	2025-03-19
Pete Sessions	🏢 House	$MO	▼ Sell	$1,001 - $15,000	2024-09-10
Ro Khanna	🏢 House	$MO	▲ Buy	$1,001 - $15,000	2024-03-20
Ro Khanna	🏢 House	$MO	▲ Buy	$1,001 - $15,000	2024-02-13
Virginia Foxx	🏢 House	$MO	▼ Sell	$1,001 - $15,000	2024-01-16
Virginia Foxx	🏢 House	$MO	▲ Buy	$1,001 - $15,000	2024-01-11
Ro Khanna	🏢 House	$MO	▼ Sell	$1,001 - $15,000	2024-01-10
Ro Khanna	🏢 House	$MO	▲ Buy	$1,001 - $15,000	2024-01-10
Virginia Foxx	🏢 House	$MO	▼ Sell	$15,001 - $50,000	2024-01-10

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricBCDAWMO

Forward yield	32786.89% ✓	6.27%
Annual dividend / share	$2.00	$4.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	22.6% ✓
Portfolio after 10y	$7.149378406802545e+21M	$77.7K ✓
Annual income after 10y	$7,106,739,309,572,423,000,000,000,000.00 ✓	$28,968.54
Total dividends collected	$7.146574325368343e+21M	$72.0K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Staples

Year-by-year: BCDAW vs MO ($10,000, DRIP)

Year	BCDAW Portfolio	BCDAW Income/yr	MO Portfolio	MO Income/yr	Gap
1← crossover	$3,289,389	$3,278,688.52	$10,558	$768.31	+$3.28M → BCDAW
2	$1,011,452,394	$1,007,932,748.46	$11,352	$1,015.87	+$1011.44M → BCDAW
3	$290,735,268,121	$289,653,014,059.08	$12,482	$1,367.86	+$290735.26M → BCDAW
4	$78,123,080,869,461	$77,811,994,132,571.95	$14,103	$1,883.39	+$78123080.86M → BCDAW
5	$19,624,484,924,633,140	$19,540,893,228,102,816.00	$16,472	$2,664.91	+$19624484924.62M → BCDAW
6	$4,608,534,766,328,053,000	$4,587,536,567,458,695,700.00	$20,024	$3,897.79	+$4608534766328.03M → BCDAW
7	$1,011,770,904,242,838,300,000	$1,006,839,772,042,867,400,000.00	$25,537	$5,933.74	+$1011770904242838.25M → BCDAW
8	$207,666,224,199,856,750,000,000	$206,583,629,332,316,930,000,000.00	$34,478	$9,476.77	+$207666224199856768.00M → BCDAW
9	$39,849,623,579,553,230,000,000,000	$39,627,420,719,659,375,000,000,000.00	$49,776	$16,022.63	+$39849623579553226752.00M → BCDAW
10	$7,149,378,406,802,546,000,000,000,000	$7,106,739,309,572,423,000,000,000,000.00	$77,699	$28,968.54	+$7.149378406802545e+21M → BCDAW

BCDAW vs MO: Complete Analysis 2026

BCDAW — Stock

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Full BCDAW Calculator →

MO — Consumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →

📬

Get this BCDAW vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BCDAW vs SCHD BCDAW vs JEPI BCDAW vs O BCDAW vs KO BCDAW vs MAIN BCDAW vs PM BCDAW vs BTI BCDAW vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.